X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-q1-profit-slips-generic-competition-forex-effects-2024-04-25/
https://www.globenewswire.com/news-release/2024/04/22/2866887/0/en/ASLAN-Pharmaceuticals-Announces-Positive-Interim-Results-From-Phase-2-Study-of-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sanofi-plans-to-launch-1-or-2-products-in-india-every-year/articleshow/108953999.cms
https://www.globenewswire.com//news-release/2024/02/23/2834220/0/en/Dupixent-dupilumab-sBLA-Accepted-for-FDA-Priority-Review-for-Treatment-of-COPD-with-Type-2-Inflammation.html
https://endpts.com/fda-sets-copd-approval-decision-date-for-sanofi-and-regenerons-dupixent-in-june/
https://www.fiercepharma.com/pharma/japan-green-lights-sanofi-and-regenerons-dupixent-hives-condition-following-fda-rejection
https://www.sanofi.com/en/media-room/press-releases/2024/2024-02-16-06-00-00-2830509
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-dupixent-treat-younger-kids-with-esophageal-condition-2024-01-25/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055
https://www.globenewswire.com//news-release/2024/01/16/2809695/0/en/Dupixent-dupilumab-U-S-Label-Updated-with-Data-Further-Supporting-Use-in-Atopic-Dermatitis-with-Moderate-to-Severe-Hand-and-Foot-Involvement.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055
https://endpts.com/kymera-doubles-down-on-protein-degraders-for-immunology-chasing-dupixent-and-sotyktu/
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-focus-12-blockbuster-drug-candidates-immunology-pipeline-2023-12-07/
https://www.fiercepharma.com/pharma/sanofi-and-regenerons-dupixent-scores-again-second-copd-trial
https://endpts.com/regeneron-expects-key-dupixent-copd-data-this-year-amid-eyleas-sales-decline-in-the-us/
https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-22-19-00-00-2764338
https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-20-21-00-00-2764252
https://www.globenewswire.com//news-release/2023/09/26/2749151/0/en/Press-Release-Dupixent-dupilumab-sBLA-for-treatment-of-eosinophilic-esophagitis-in-children-aged-1-to-11-accepted-for-FDA-Priority-Review.html
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-lifts-earnings-outlook-dupixent-sales-new-drug-launches-2023-07-28/
https://www.prnewswire.com/news-releases/20-of-dupixent-treated-atopic-dermatitis-patients-are-refractory-to-the-drug-marketvue-report-301886427.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055
https://www.indianpharmapost.com/news/dupixent-is-now-approved-in-india-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis-14387
https://www.fiercepharma.com/pharma/dupixent-leading-way-copd-sanofi-set-play-big-boys-and-girls-respiratory-diseases
https://www.globenewswire.com/news-release/2023/05/21/2672905/0/en/Dupixent-dupilumab-Late-breaking-Phase-3-COPD-Results-Presented-at-ATS-and-Simultaneously-Published-in-the-New-England-Journal-of-Medicine.html
https://www.sanofi.com/en/media-room/press-releases/2023/2023-05-08-12-30-00-2663289
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-21-06-00-00-2630956
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-23-06-00-00-2632822
https://www.nasdaq.com/articles/sanofis-sny-dupixent-gets-eu-nod-for-eczema-in-young-kids
https://www.fiercepharma.com/pharma/will-sanofi-and-regenerons-dupixent-be-game-changer-or-just-another-antibody-copd-scrapheap
https://www.globenewswire.com/news-release/2023/03/18/2629819/0/en/Press-Release-Dupixent-dupilumab-late-breaking-data-at-AAD-show-significant-improvements-in-signs-and-symptoms-of-moderate-to-severe-atopic-hand-and-foot-dermatitis.html
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-07-06-00-00-2621670
https://www.globenewswire.com/news-release/2023/03/07/2621674/0/en/Dupixent-dupilumab-Application-for-Treatment-of-Chronic-Spontaneous-Urticaria-CSU-in-Adults-and-Adolescents-Aged-12-Years-and-Older-Accepted-for-FDA-Review.html
https://www.globenewswire.com/news-release/2023/02/03/2601072/0/en/Press-Release-Strong-sales-performance-and-double-digit-EPS-growth-marking-the-achievement-of-the-2022-profitability-milestone.html
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-forecasts-fx-adjusted-profit-growth-dupixent-prescriptions-2023-02-03/
https://www.sanofi.com/en/media-room/press-releases/2023/2023-01-30-06-00-00-2597236
https://www.globenewswire.com/news-release/2023/01/27/2596596/0/en/Dupixent-dupilumab-Recommended-for-Expanded-EU-Approval-by-the-CHMP-to-Treat-Children-as-Young-as-Six-Months-Old-with-Severe-Atopic-Dermatitis.html
https://endpts.com/brands-in-demand-keytruda-dupixent-and-ozempic-lead-2023-new-sales-predictions-evaluate-report/
https://www.prnewswire.com/news-releases/positive-dupixent-dupilumab-phase-3-results-in-adults-and-adolescents-with-eosinophilic-esophagitis-published-in-the-new-england-journal-of-medicine-301708622.html
https://www.globenewswire.com//news-release/2022/12/21/2578278/0/en/Press-Release-Positive-Dupixent-dupilumab-Phase-3-results-in-adults-and-adolescents-with-eosinophilic-esophagitis-published-in-the-New-England-Journal-of-Medicine.html
https://www.sanofi.com/en/media-room/press-releases/2022/2022-12-21-22-30-00-2578278
https://www.nasdaq.com/articles/regeneron-sanofi:-dupixent-approved-in-eu-for-prurigo-nodularis
https://www.sanofi.com/en/media-room/press-releases/2022/2022-12-16-12-30-00-2575389
https://www.prnewswire.com/news-releases/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-eosinophilic-esophagitis-301705159.html
https://www.globenewswire.com/news-release/2022/12/15/2574421/0/en/ASLAN-Pharmaceuticals-Announces-First-Patient-Screened-in-Study-of-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients.html
https://www.fiercepharma.com/marketing/abbvies-rinvoq-retakes-crown-sanofis-dupixent-top-tv-drug-ad-spender-november
https://endpts.com/uk-regulator-warns-of-severe-eye-reactions-following-use-of-sanofi-and-regenerons-dupixent/
https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-11-12-00-00-2554131
https://www.fiercepharma.com/marketing/sanofis-dupixent-narrowly-beats-out-rinvoq-become-top-tv-drug-ad-spender-october
https://www.expresspharma.in/sanofi-sees-faster-profit-growth-on-dupixent-flu-vaccine/
Market Place
Share 
